<DOC>
	<DOC>NCT02016716</DOC>
	<brief_summary>Purpose of this study is to evaluate the 2 formulations of Romosozumab (AMG785) in Postmenopausal Women With Osteoporosis.</brief_summary>
	<brief_title>A Randomized Phase 3 Study to Evaluate 2 Different Formulations of Romosozumab in Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Postmenopausal women with osteoporosis at high risk for fracture defined as BMD Tscore â‰¤ 2.50 at the lumbar spine, total hip, or femoral neck AND a history of fragility fracture or at least 2 other risk factors BMD T score &lt; 3.50 at the total hip or femoral neck. History of hip fracture. History of metabolic or bone disease (except osteoporosis). Use of agents affecting bone metabolism. Vitamin D insufficiency. History of solid organ or bone marrow transplants. Hyper or hypocalcemia. Hyper or hypothyroidism. Hyper or hypoparathyroidism.</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Postmenopausal Osteoporosis</keyword>
</DOC>